Overview

Tofacitinib Combined With Chidamide in R/R ENKTCL

Status:
Not yet recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This study is to explore the efficacy and safety of tofacitinib combined with chidamide in patients with relapsed and refractory extranodal NK/T cell lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

Sichuan University

Treatments:

Tofacitinib